Biomolecular corona on nanoparticles: a survey of recent literature and its implications in targeted drug delivery

Achieving controlled cellular responses of nanoparticles (NP) is critical for the successful development and translation of NP-based drug delivery systems. However, precise control over the physicochemical and biological properties of NPs could become convoluted, diminished, or completely lost as a result of the adsorption of biomolecules to their surfaces. Characterization of the formation of the “biomolecular” corona has thus received increased attention due to its impact on NP and protein structure as well as its negative effect on NP-based targeted drug delivery. This review presents a concise survey of the recent literature concerning the importance of the NP-biomolecule corona and how it can be utilized to improve the in vivo efficacy of targeted delivery systems.

[1]  Shu Zhang,et al.  Preformed albumin corona, a protective coating for nanoparticles based drug delivery system. , 2013, Biomaterials.

[2]  Morteza Mahmoudi,et al.  Protein Corona Composition of Superparamagnetic Iron Oxide Nanoparticles with Various Physico-Chemical Properties and Coatings , 2014, Scientific Reports.

[3]  Andrew Emili,et al.  Nanoparticle size and surface chemistry determine serum protein adsorption and macrophage uptake. , 2012, Journal of the American Chemical Society.

[4]  Morteza Mahmoudi,et al.  Personalized protein coronas: a "key" factor at the nanobiointerface. , 2014, Biomaterials science.

[5]  Sara Linse,et al.  Understanding the nanoparticle–protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles , 2007, Proceedings of the National Academy of Sciences.

[6]  Seungpyo Hong,et al.  Prolonged blood circulation and enhanced tumor accumulation of folate-targeted dendrimer-polymer hybrid nanoparticles. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[7]  James E Bear,et al.  PEGylated PRINT nanoparticles: the impact of PEG density on protein binding, macrophage association, biodistribution, and pharmacokinetics. , 2012, Nano letters.

[8]  Warren C. W. Chan,et al.  Polyethylene glycol backfilling mitigates the negative impact of the protein corona on nanoparticle cell targeting. , 2014, Angewandte Chemie.

[9]  Candace C. Fleischer,et al.  Secondary Structure of Corona Proteins Determines the Cell Surface Receptors Used by Nanoparticles , 2014, The journal of physical chemistry. B.

[10]  Ryan M. Pearson,et al.  Understanding nano-bio interactions to improve nanocarriers for drug delivery , 2014 .

[11]  Marco P Monopoli,et al.  Biomolecular coronas provide the biological identity of nanosized materials. , 2012, Nature nanotechnology.

[12]  L. Vroman,et al.  Interaction of high molecular weight kininogen, factor XII, and fibrinogen in plasma at interfaces. , 1980, Blood.

[13]  K. Landfester,et al.  Protein corona change the drug release profile of nanocarriers: the "overlooked" factor at the nanobio interface. , 2014, Colloids and surfaces. B, Biointerfaces.

[14]  Ryan M. Pearson,et al.  Dendritic nanoparticles: the next generation of nanocarriers? , 2012, Therapeutic delivery.

[15]  S. Radford,et al.  Nucleation of protein fibrillation by nanoparticles , 2007, Proceedings of the National Academy of Sciences.

[16]  Nicholas A Peppas,et al.  Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. , 2006, International journal of pharmaceutics.

[17]  W. Kreyling,et al.  Serum protein identification and quantification of the corona of 5, 15 and 80 nm gold nanoparticles , 2013, Nanotechnology.

[18]  Philip M. Kelly,et al.  Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. , 2013, Nature nanotechnology.

[19]  Gert Storm,et al.  Sheddable Coatings for Long-Circulating Nanoparticles , 2007, Pharmaceutical Research.

[20]  Shaojun Dong,et al.  pH-dependent protein conformational changes in albumin:gold nanoparticle bioconjugates: a spectroscopic study. , 2007, Langmuir : the ACS journal of surfaces and colloids.

[21]  Sara Linse,et al.  Complete high‐density lipoproteins in nanoparticle corona , 2009, The FEBS journal.

[22]  Nunzio Bottini,et al.  Surface polyethylene glycol conformation influences the protein corona of polyethylene glycol-modified single-walled carbon nanotubes: potential implications on biological performance. , 2013, ACS nano.

[23]  D. Simberg,et al.  Interactions of nanoparticles with plasma proteins: implication on clearance and toxicity of drug delivery systems , 2011, Expert opinion on drug delivery.

[24]  M. D. Blanco,et al.  Targeted Nanoparticles for Cancer Therapy , 2012 .

[25]  M. Bawendi,et al.  Renal clearance of quantum dots , 2007, Nature Biotechnology.

[26]  M. Uesaka,et al.  Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. , 2011, Nature nanotechnology.

[27]  Yoon Yeo,et al.  Recent advances in stealth coating of nanoparticle drug delivery systems. , 2012, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

[28]  K. Dawson,et al.  Magnetic nanoparticles to recover cellular organelles and study the time resolved nanoparticle-cell interactome throughout uptake. , 2014, Small.

[29]  N. Durán,et al.  Influence of protein corona on the transport of molecules into cells by mesoporous silica nanoparticles. , 2013, ACS applied materials & interfaces.

[30]  Mauro Ferrari,et al.  Shrinkage of pegylated and non-pegylated liposomes in serum. , 2014, Colloids and surfaces. B, Biointerfaces.

[31]  Frank A. Witzmann,et al.  Silver Nanoparticle Protein Corona Composition in Cell Culture Media , 2013, PloS one.

[32]  J. Karp,et al.  Nanocarriers as an Emerging Platform for Cancer Therapy , 2022 .

[33]  R. Bucala,et al.  Macrophage migration inhibitory factor. , 2005, Critical care medicine.

[34]  S. Donnelly,et al.  Macrophage migration inhibitory factor: a neuroendocrine modulator of chronic inflammation. , 2003, The Journal of endocrinology.

[35]  Darren J. Martin,et al.  Cryptic epitopes of albumin determine mononuclear phagocyte system clearance of nanomaterials. , 2014, ACS nano.

[36]  R. Kok,et al.  Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status. , 2013, Advanced drug delivery reviews.

[37]  M. Ferrari,et al.  The nano-plasma interface: Implications of the protein corona. , 2014, Colloids and surfaces. B, Biointerfaces.

[38]  Wenwan Zhong,et al.  Size and Surface Functionalization of Iron Oxide Nanoparticles Influence the Composition and Dynamic Nature of Their Protein Corona , 2014, ACS applied materials & interfaces.

[39]  B. Jonsson,et al.  Adsorption of Human Carbonic Anhydrase II Variants to Silica Nanoparticles Occur Stepwise: Binding Is Followed by Successive Conformational Changes to a Molten-Globule-like State , 2000 .

[40]  J. Vallée,et al.  Ex situ evaluation of the composition of protein corona of intravenously injected superparamagnetic nanoparticles in rats. , 2014, Nanoscale.

[41]  K. Dawson,et al.  Detecting Cryptic Epitopes Created by Nanoparticles , 2006, Science's STKE.

[42]  Edouard C. Nice,et al.  Differential roles of the protein corona in the cellular uptake of nanoporous polymer particles by monocyte and macrophage cell lines. , 2013, ACS nano.

[43]  T. Xia,et al.  Understanding biophysicochemical interactions at the nano-bio interface. , 2009, Nature materials.

[44]  Jianjun Cheng,et al.  Protein corona significantly reduces active targeting yield. , 2013, Chemical communications.

[45]  K. Dawson,et al.  Systematic investigation of the thermodynamics of HSA adsorption to N-iso-propylacrylamide/N-tert-butylacrylamide copolymer nanoparticles. Effects of particle size and hydrophobicity. , 2007, Nano letters.

[46]  Andrew Emili,et al.  Protein corona fingerprinting predicts the cellular interaction of gold and silver nanoparticles. , 2014, ACS nano.

[47]  R. Jain,et al.  Strategies for advancing cancer nanomedicine. , 2013, Nature materials.

[48]  R. Zhou,et al.  Binding of blood proteins to carbon nanotubes reduces cytotoxicity , 2011, Proceedings of the National Academy of Sciences.

[49]  Iseult Lynch,et al.  Formation and characterization of the nanoparticle-protein corona. , 2013, Methods in molecular biology.

[50]  L. Zhang,et al.  Nanoparticles in Medicine: Therapeutic Applications and Developments , 2008, Clinical pharmacology and therapeutics.

[51]  Kenneth A. Dawson,et al.  Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts , 2008, Proceedings of the National Academy of Sciences.

[52]  S. Retterer,et al.  Dynamic development of the protein corona on silica nanoparticles: composition and role in toxicity. , 2013, Nanoscale.

[53]  Parag Aggarwal,et al.  Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. , 2009, Advanced drug delivery reviews.

[54]  Andrzej S Pitek,et al.  Reversible versus irreversible binding of transferrin to polystyrene nanoparticles: soft and hard corona. , 2012, ACS nano.

[55]  Stefan Tenzer,et al.  Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology. , 2013, Nature nanotechnology.

[56]  Albert Duschl,et al.  Interaction of nanoparticles with proteins: relation to bio-reactivity of the nanoparticle , 2013, Journal of Nanobiotechnology.

[57]  J. Hubbell,et al.  Translating materials design to the clinic. , 2013, Nature materials.